The central question of this study is to understand whether dietary quercetin enrichment attenuates physiologic, histological, and biochemical indices of cardiac pathology. r What is the main finding and its importance?
Introduction
Duchenne muscular dystrophy (DMD) is an X-linked genetic disease that causes premature mortality in early adulthood (Emery, 1993) . Although multiple forms of muscular dystrophy exist, DMD is the most prevalent form of the disease, leading to a systemic dysfunction of the structural protein dystrophin (Darras, 1990) . As dystrophin is a key protein mediating membrane stabilization during muscular contraction, the physiological consequences of DMD include fragile cell membranes, ionic disturbances, metabolic dysfunction and cell death. Clinically, DMD is characterized by time-dependent progressive muscle wasting and weakness with a wide range of heterogeneity. Although respiratory failure is a common cause of death, cardiac complications attributable to dystrophin deficiency now comprise up to 40% of all deaths resulting from DMD (Costanza & Moggio, 2010) . Age-dependent cardiopathology is evident in extensive cardiac remodelling, contractile dysfunction, fibrotic tissue deposition, dilatation of cardiac cavities and the occurrence of heart failure (Finsterer & Cripe, 2014) . Compounding the matter, cardiac pathology is further impacted by standard muscular dystrophy treatments, such as the long-term use of corticosteroids (Sali et al. 2012) . Accordingly, novel approaches to treat cardiac pathologies in the dystrophic heart are needed.
Countermeasure efficacy is typically initiated with animal investigations, most of which use mouse models that recapitulate DMD. The mdx mouse is an inbred C57BL/10 mouse strain developed through a spontaneous mutation of dystrophin and is one of the most widely used because of the respiratory complications and mild cardiac distress characteristics that parallel the disease in humans. Many interventions attenuate the faceted cardiac pathology in dystrophic mouse models, including antioxidant therapy (Williams & Allen, 2007) , anti-inflammatory approaches (Finsterer & Cripe, 2014) and exercise . Recent approaches also include induction of adaptive gene transcripts, including the sirtuin 1 (SIRT1)-peroxisome proliferator-activated receptor γ coactivator 1α axis, that support mitochondrial biogenesis concomitant to structural protein fortification through upregulation of utrophin (Hollinger et al. 2013) . Recent findings indicate that induction of PGC-1α alleviates many aspects of dystrophinopathy in skeletal muscle (Selsby et al. 2012; Hollinger et al. 2013) ; however, physiological evidence of cardioprotection is lacking.
As a potential solution to DMD cardiopathology, early evidence indicates that dietary application of polyphenols attenuates the multifaceted pathological mechanisms in a single therapeutic agent. Fundamental support of this position includes the fact that polyphenols combat oxidative stress (Vásquez-Garzón et al. 2009 ), chronic inflammation (Boots et al. 2008b ) and cardiac pathology (Han et al. 2009 ) and induce adaptive gene expression through activation of SIRT/PGC-1α (Lagouge et al. 2006; Hollinger et al. 2015) . Of the multiple polyphenols present in the human diet, quercetin (3,3 ,4 ,5,7-pentahydroxyflaone) makes up the majority of total polyphenol ingestion (Chun et al. 2007) . Quercetin is a safe, naturally occurring flavonol with anti-inflammatory and antioxidant effects and is also a potent SIRT1/PGC-1α activator capable of antioxidant upregulation, mitochondrial biogenesis and induction of transcripts associated with slow skeletal muscle, including the dystrophin-related protein utrophin (Ballmann et al. 2015; Hollinger et al. 2015; Selsby et al. 2016) . Independently, quercetin prevents or limits histological and biochemical indices of cardiac dysfunction (Ballmann et al. 2015) . Previously published work indicated that a 6 month dietary quercetin intervention, at a moderate dose of 0.2% total dietary intake, elevated bioavailable quercetin concentrations in plasma and alleviated indices of pathology in dystrophin-deficient skeletal muscle . However, it is currently less clear to what extent dietary quercetin enrichment impacts dystrophin-deficient hearts. Preliminary data from our laboratory suggested that early short-term dietary quercetin enrichment in mdx mice increased mitochondrial biogenesis, antioxidant protein abundance and utrophin expression and decreased matrix metalloprotease 9 (MMP9) in young mdx mouse hearts while also attenuating cardiac and fibrotic damage in older mdx mice (Ballmann et al. 2015) . Although these data are compelling, the physiological implications of these findings are uncertain. Also unknown is whether long-term dietary quercetin enrichment would benefit physiological and histological outcomes in dystrophin-deficient hearts. Hence, the purpose of the present investigation was to assess the extent to which chronic dietary quercetin enrichment alters physiological heart performance in addition to markers of inflammation and remodelling in dystrophic hearts.
Methods

Study design and ethical approval
The study was performed in accordance with the principles established by the American Physiological Society and was approved by the Auburn University Animal Care and Use Committee. Data assessing respiratory and diaphragm function from these animals have been published previously (Selsby et al. 2016) . The mdx mice and C57BL/10 control mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). Beginning at 2 months of age, the mice were housed on a 12 h-12 h reverse light-dark cycle. The mdx mice were randomized, and diets consisted of either untreated standard rodent chow ('mdx' , n = 8) or 0.2% quercetin-fortified rodent chow ('mdx-Q' , n = 8; Bioserv Inc., Frenchtown, NJ, USA), and control C57BL/10 mice were fed standard rodent chow ('C57' , n = 8) for the total experimental time of 12 months. Throughout the investigation, food and water were provided ad libitum. As there was some attrition (death) over time and not all animals were represented for each measure, the sample number for a given measure is given in the figure legends.
Functional cardiac assessment (7 T MRI)
Cardiac function assessments were performed using by 7 T magnetic resonance imaging (MRI; Siemens Corp., USA) at Auburn University. Mice were scanned while anaesthetized with isoflurane in oxygen and instrumented for ECG, respiration and body temperature. Mice were scanned using a custom-made small-bore quadrature radio frequency coil and custom sequence program. Mice underwent MRI at 2, 10 and 14 months of age. Cardiac cine sets of 10-15 temporal frames were obtained including two-chamber (left atria and ventricle only) long-axis, four-chamber (all atria and ventricles) long-axis and two-chamber (right and left ventricle only) short-axis views to ensure complete three-dimensional depiction of whole-heart function. The MRI was gated to the ECG and respiration to ensure consistent imaging of the entire cardiac cycle.
Assessment of cardiac function was performed by two trained analysts blinded to animal strain and treatment and averaged. Cinematic audio-video interleaves were created to determine and isolate systolic and diastolic phases. Cardiac function parameters were quantified using ImageJ software (National Institutes of Health, Bethesda, MD, USA), where longitudinal and short-axis dimensions were measured at systolic and diastolic phases. From these measurements, the ejection fraction (EF), stroke volume (SV), cardiac output (CO), end-diastolic volume (EDV), end-systolic volume (ESV), left ventricular end-diastolic dimension (LVEDD), left ventricular end-systolic dimension (LVESD), fractional shortening (%FS), systolic wall thickness (SWT) and %SWT were calculated during systole and diastole (Beyers et al. 2012) .
Quantification of spontaneous physical activity
In the final week of treatment, all mice were observed for instances of the following nine typical murine activities: sitting, grooming, eating/drinking, socializing, standing, walking, wall pacing, running and jumping. Quantification of physical activity involved a species-independent technique that incorporates a mouse behaviour ethogram (repertoire of typical mouse activities) using '0-1 focal sampling time record' (Martin & Bateson, 2007) . Accordingly, the observance of a mouse performing a particular activity (sitting, grooming, etc.) was recorded as 1. Activity counts were collected by two investigators during two separate recording sessions. Within each recording session, activity was quantified every 15 s for 10 min, yielding 40 total time periods per observation session. In total, 20 min of animal activity were recorded for the final values, and activity counts were performed at a common time of day at the end of the photo light and photo dark periods. In order to gauge total activity in a common metric, time-normalized activities were scaled based on approximate metabolic costs (sitting and grooming = 1, eating/drinking, socializing and standing = 1.5, walking and wall pacing = 2, running = 2.5 and jumping = 3).
Tissue harvesting and storage
After the 12 month experimental treatment, all mice were weighed and anaesthetized by inhalation of isoflurane until a surgical plane was established. Animals were then killed by cardiac excision. Hearts were rinsed in chilled 10 mM PBS, blotted dry, weighed, placed in optimal cutting temperature compound, and flash frozen in 2-methyl-butane chilled with liquid nitrogen to reduce C. Ballmann and others the risk of freeze fracture. After freezing, hearts were maintained at −80°C until subsequent assay.
Histology and immunofluorescence
In blinded conditions, hearts were cut into sections 10 μm thick on a Shandon Cryotome cryostat (−30°C) and adhered to 1 mm microscope slides (Fischer Scientific, Pittsburgh, PA, USA). Selected slides were stained by a modified Haematoxylin and Eosin-Y (H&E) histological procedure as a measure of cardiac damage. Stained slides were imaged via light microscopy with Nikon software (Melville, NY, USA). For each slide, 10-15 non-overlapping ×40 magnification images were obtained to characterize and ensure consistent representation of the entire heart cross-section. Images were then analysed using ImageJ software (National Institutes of Health) and results expressed as damaged tissue relative to healthy tissue.
Cardiac levels of fibronectin and metalloprotease 9 (MMP9) were quantified using a histological immunofluorescence procedure. Cardiac cross-sections were fixed with a 10% formalin solution, rinsed, and permeabilized with Triton X-100 in 1% sodium citrate solution. Slides were rinsed in 10 mM PBS and blocked with 3% bovine serum albumin and 20% goat serum. Slides were allocated for incubation with primary antibodies directed against the followingproteins of interest: fibronectin (1:500 dilution; F3648; Sigma-Aldrich) and MMP9 (1:500 dilution; sc-6840; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Tissue cross-sections were incubated with corresponding secondary antibodies for fluorescein isothiocyanate (FITC, 1:500 dilution; sc-2365; Santa Cruz Biotechnology; or 1:500 dilution; sc-2010; Santa Cruz Biotechnology) and/or Texas Red (TRITC, 1:500 dilution; T1-1000; Vector Laboratories Inc.) fluorescent tags. Slides were sealed with 4 ,6-diamidino-2-phenylindole (DAPI; Vector Laboratories Inc.) mounting medium and imaged with a fluorescent imaging microscope (Nikon, Melville, NY, USA). Randomized images (10-15) were obtained as previously discussed with corresponding TRITC, FITC and DAPI filters. All images were collected in identical capture conditions by the same blinded technician. To confirm antibody specificity, negative controls (primary only or secondary only) were also imaged in identical exposure conditions. Mean fluorescent intensity per unit area (in micrometres squared) was quantified using Nikon Software in blinded conditions.
Western blotting
Myocardial protein was obtained from frozen heart samples and separated by SDS-PAGE techniques (60 μg per sample) on 6-12% polyacrylamide gels via electrophoresis. Proteins were transferred to activated polyvinylidene difluoride (PVDF) membranes, stained, and imaged with Ponceau stain to ensure equal loading. Membranes were exposed to primary antibodies for the protein of interest, as follows: cytochrome c (1:500 dilution; sc-7159; Santa Cruz Biotechnology), citrate synthase (1:500 dilution; sc-390693; Santa Cruz Biotechnology), CD64 (1:500 dilution; sc-15364p; Santa Cruz Biotechnology), cyclooxygenase 2 (COX2, 1:1000 dilution; CS-12282; Cell Signaling Technology Inc., Danvers, MA, USA), F4/80 (1:200 dilution; sc-25830; Santa Cruz Biotechnology), glutathione peroxidase (GPX) (1:500 dilution; sc-74498; Santa Cruz Biotechnology), inducible nitric oxide synthase (1:1000 dilution; CS-13120; Cell Signaling Technology Inc.), nuclear factor-κB (NFκB, 1:1000 dilution; CS-8242; Cell Signaling Technology Inc.), phospho-NFκB (1:1000 dilution; CS-3033; Cell Signaling Technology Inc.), nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha (IκBα) (1:1000 dilution; CS-4814; Cell Signaling Technology Inc.), phospho-IκBα (1:1000 dilution; CS-2859; Cell Signaling Technology Inc.), OxPhos Complex Kit (1:5000 dilution; 457999; Invitrogen), PGC-1α (1:500 dilution; sc-13067; Santa Cruz Biotechnology), superoxide dismutase 2 (SOD2, 1:500 dilution; sc-30080; Santa Cruz Biotechnology) and transforming growth factor-β1 (TGF-β1, 1:500 dilution; sc-146; Santa Cruz Biotechnology). Membranes were exposed to the corresponding IgG-horseradish peroxidase (HRP) secondary antibodies for chemiluminescence detection, as follows: anti-rabbit IgG HRP linked (1:1000 dilution; CS-7074; Cell Signaling Technology Inc.) and anti-mouse IgG HRP linked (1:1000 dilution; CS-7076: Cell Signaling Technology Inc.). Membranes were reprobed and exposed to corresponding normalizing protein primary antibodies as follows: α-tubulin (1:1000 dilution; DHSB), β-actin (1:1000 dilution; CS-4970; Cell Signaling Technology Inc.) and GAPDH (1:1000; GP239; GenTex, Zeeland, MI, USA). Corresponding secondary antibodies previously mentioned were used for chemiluminescence detection. According to the manufacturer's instructions, Western blots were normalized to corresponding normalizing protein or Ponceau stain (OxPhos assay only) and were analysed using a UVP LLC digital imaging device (Ultraviolet Products LLC, Upland, CA, USA). All experiments and analysis were conducted by a blinded technician.
Statistical analyses
End-point measures were analysed by one-way ANOVA. A two-way (strain × treatment) repeated-measures (2 month × 10 month × 14 month) ANOVA was used to test differences for our key dependent variables using SPSS 20 (IBM, New York, NY, USA). Tukey's post hoc tests were Data are means ± SD. n = 6-8 per group.
performed as indicated. Significance was set at P ࣘ 0.05 a priori. Data are presented as means ± SD.
Results
Animal characteristics
Animal characteristic data at the end of the 12 month treatment period are presented in (Table 1) . Changes in body weight, food consumption and respiratory function have been reported previously (Selsby et al. 2016) . No differences existed between groups for body weight (P = 0.322), absolute heart weight (in milligrams; P = 0.536) or relative heart weight (in milligrams per gram; P = 0.166).
Cardiac function
Cardiac function measured by MRI was quantified at 2, 10 and 14 month time points. Dependent variables included HR, EF, SV, CO, EDV, ESV, LVEDD, LVESD, %FS, SWT and %SWT (Table 2) . At the baseline 2 month examination, no differences existed between C57, untreated mdx and quercetin-fed mdx mice. Similar to baseline data, the 10 month cardiac scan did not find a difference between C57, untreated mdx and quercetin-fed mdx mice for any cardiac performance variables. However, baseline-to-10 month differences were observed in mdx-Q mice for EF, EDV and ESV. The LVEDD was elevated in mdx-Q mice at both 10 and 14 month scans. Similar time-dependent differences existed for all groups at the 14 month scan in that HR was lower than the observed baseline values. Moreover, differences were observed at 14 months, with untreated mdx and mdx-Q mean values being elevated over baseline values for EF, CO and FS. Given these outcomes, it was not surprising that the converse was true in that EDV, ESV and LVESD were higher in untreated mdx and mdx-Q mice compared with the 2 month scans. The only strain-dependent changes observed currently were at the 14 month scan, probably indicating age-related pathology in the mdx mouse model. Specifically, at the 14 month time point, mdx and mdx-Q mice had lower FS and higher LVESD compared with C57. Perhaps most interestingly, no treatment-specific differences existed at the 14 month cardiac scan.
Western blotting
Ventricular tissue harvested at 14 months was assessed by Western blotting to determine the relative abundance for proteins of interest related to the themes based on the influence of quercetin on PGC-1α and mitochondrial fortification, endogenous antioxidant enzyme content and inflammatory function.
Mitochondrial content, including mean responses for cardiac PGC-1α, cytochrome c, citrate synthase, their respective normalization proteins and representative images are presented in Fig. 1A-D . The protein abundance of PGC-1α was elevated in mdx-Q-treated mice versus control C57 and mdx mice (P = 0.037 and P = 0.018, respectively). As PGC-1α is a fundamental transcription cofactor for mitochondrial biogenesis, strategic downstream mitochondrial proteins were also investigated. Differences in cytochrome c protein abundance were observed between C57 and mdx mice (P = 0.047), while treatment differences between mdx and mdx-Q mice (P = 0.027) were also present. Citrate synthase, found exclusively in the mitochondria, was elevated in mdx-Q mice versus C57 (P < 0.001) and mdx mice (P < 0.001).
Electron transport chain complex proteins I-V in 14-month-old hearts, representative images and Ponceau normalization blots (as recommended by the manufacturer) are presented in Fig. 2A-F . Sample loading was normalized to Ponceau band density between the target ranges of 20 and 57 kDa. A consistent treatment difference, untreated mdx versus mdx-Q mice, was present for all five complexes (complex I, P = 0.021; complex II, P = 0.017; complex III, P = 0.013; complex IV, P = 0.019; and complex V, P = 0.024). No strain differences were observed for mitochondrial complex protein abundance from 14-month-old hearts.
Endogenous antioxidant enzyme content for SOD2, GPX, normalization protein and representative images from 14-month-old hearts are presented in Fig. 3A-C . The protein content of SOD2 was higher in mdx-Q compared with mdx mice (P = 0.040). The protein content of GPX was elevated in hearts from 14-month-old mdx-Q-treated mice compared with mdx (P = 0.032) and C57 mice (P = 0.039). Collectively, long-term quercetin enrichment appears to stimulate myocardial mitochondrial biogenesis markers and enzymatic antioxidants.
Inflammatory signalling markers for the NFκB pathway were examined. Specifically, representative images for IKBα, p-IKBα, NFκB and p-NFκB with normalization proteins are presented in Fig. 4A -E. The IKBα was severalfold higher in mdx-Q mice (P < 0.001) compared with C57 or mdx mice. Conversely, the NFκB activator p-IKBα was lower in mdx-Q-treated mice (P < 0.001) compared with both C57 and untreated mdx groups. In 14-month-old hearts, NFκB expression was higher in mdx versus C57 mice, while mdx-Q-treated hearts were statistically similar to C57. Furthermore, phosphorylated (activated) NFκB was lower in mdx-Q-treated mice compared with both C57 (P = 0.033) and untreated mdx mice (P < 0.001).
Inflammatory and fibrotic mediators COX2, TGF-β1, F4/80, CD64, normalization protein and representative images are presented in Fig. 5A -E. The protein content of COX2 was lower in mdx-Q-treated mice (P < 0.001) compared with both C57 and mdx mice. The TGF-β1 was lower in mdx-Q compared with mdx mice (P = 0.010), although differences between mdx and C57 mice were not present. The macrophage marker F4/80 was numerically but non-statistically elevated in mdx compared with C57 mice. Statistical differences were present only for mdx-Q versus mdx treatment (P = 0.005). CD64, a mouse homolog of epidermal growth factor (EGF)-like module-containing mucin-like hormone receptor-like 1 found exclusively in macrophages, was also used to assess immune cell infiltration indirectly. No strain or treatment differences were observed in 14-month-old hearts.
Histology
Histological assays were performed on hearts of 14-month-old mice in order to quantify metrics for tissue remodelling and dystrophin-associated glycoprotein complex (DCG) assembly. Tissue remodelling assay outcomes for MMP9, fibronectin, H&E and the corresponding representative images are presented in Fig. 6A -F. In these measures, mdx was consistently higher than C57, which indicates histopathological injury and cardiac remodelling. Importantly, dietary quercetin enrichment ablated or attenuated these pathological changes in that treatment differences were present between mdx and mdx-Q hearts for fibronectin and H&E. Differences between mdx and mdx-Q mice were not present for MMP9 (P = 0.076).
Spontaneous physical activity
Spontaneous physical activity was observed in C57 mdx and mdx-Q mice during the final week of treatment. Spontaneous activity counts for the nine activities are presented in Table 3 . Analyses of activity data in 14-month-old mice indicated that untreated mdx mice were less active than C57 mice. Moreover, dietary enrichment with quercetin corrected this deficit but also appeared to drive active behaviours. Given the advanced age of mice in all groups, it was not surprising that mdx mice engaged in similar amounts of moderate (standing and walking) and the remaining high-intensity activities (wall pacing and jumping) compared with the C57 mice. Remarkably, mdx-Q mice were different from untreated mdx mice for all nine activities quantified. Specifically, mdx-Q mice engaged in less frequent sitting and more activity for all other activity variables. Perhaps most interestingly, mdx-Q-fed mice were different from age-matched C57 mice, performing less sitting and more eating/drinking, standing, walking and running. The activity metric results for all nine observed animal activities are presented in Fig. 7 . The findings indicate that mdx mice were far less active than C57 mice and that mdx-Q mice exhibited significantly more 24.6 ± 4.2 13.6 ± 6.9 3.5 ± 5.0 11.1 ± 7.4 3.5 ± 3.9 10.6 ± 13.3 8.1 ± 12.1 0.4 ± 1.1 1.9 ± 5.1 mdx 33.4 ± 4.3 * 11.9 ± 6.5 3.1 ± 3.2 2.4 ± 1.4 * 3.1 ± 4.3 7.3 ± 8.2 0.9 ± 3.6 0.0 ± 0.0 * 2.1 ± 5.7 mdx-Q 8.4 ± 6.7 * † 18.3 ± 6.6 † 12.6 ± 8.3 * † 15.9 ± 4.8 † 16.1 ± 9.3 * † 25.5 ± 6.8 * † 17.3 ± 9.4 † 6.0 ± 12.5 * † 7.0 ± 6.3 † Data are means ± SD. n = 6-8 per group. * Significantly different from age-matched C57 mice. † Significantly different from age-matched mdx mice.
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high-intensity physical activity than either mdx or C57 mice.
Discussion
Care for respiratory function in DMD patients has improved to the point that cardiac dysfunction and ventricular pump failure are among the leading causes of morbidity and mortality (Shirokova & Niggli, 2013) . In the absence of a cure or pragmatic long-term therapies, our laboratory group has explored novel and practical means to mitigate DMD pathology. Preliminary data indicate that induction of PGC-1α ameliorates many of the pathological processes in mdx mice (Selsby et al. 2012; Hollinger et al. 2013) . Of note, dietary quercetin consumption may be a potential avenue to activate the Sirtuin1-PGC-1α metabolic axis and alleviate many factors of the multifaceted pathology of DMD in mdx mice (Ballmann et al. 2015; Hollinger et al. 2015) . Previous findings in hearts from young mdx mice indicate that short-term dietary quercetin enrichment in mdx mice is associated with improved metrics of mitochondrial biogenesis, antioxidant enzyme abundance and utrophin expression. These treatment-dependent outcomes were associated with attenuated histological indices of fibrotic damage in hearts from 9-month-old quercetin-treated mdx mice (Ballmann et al. 2015) . Based on this existing knowledge, the present research study was undertaken to determine whether long-term dietary quercetin enrichment imparts physiological improvements in cardiac function and physical activity in addition to preserving the tissue-level protection observed previously in younger mice. Novel findings from the present study demonstrate that long-term quercetin enrichment does not appear to preserve cardiac function in mdx mice up to the age of 14 months. These findings, in combination with a companion study from our research group, suggest that long-term quercetin feeding does not benefit physiological outcomes in striated muscle (Selsby et al. 2016) . Nonetheless, histological and biochemical secondary measures from these 14-month-old hearts appeared to confirm our previous findings and suggest that quercetin-dependent benefits may have occurred in post-mortem histological and biochemical examination of cardiac tissues (Ballmann et al. 2015) . These latter findings accompany significant increases in spontaneous physical activity in quercetin-fed mdx mice and suggest that quercetin does improve long-term outcomes in the face of dystrophin deficiency.
Cardiac function
Previous reports have suggested that mdx mice develop cardiac dysfunction throughout their lifespan (see selected review, Shirokova & Niggli, 2013) . However, while 2-month-old mdx mice have normal heart function compared with control strains, they are still subject to damage attributable to mechanical overload (Danialou et al. 2001; Quinlan et al. 2004) . In a time-dependent manner, mdx mouse hearts become increasingly fibrotic and exhibit signs of contractile dysfunction by the age of 9 months (Shirokova & Niggli, 2013) .
In the present study, mdx strain-dependent declines in CO, FS, EDV and ESV (and the corresponding dimensions) were observed. These age-dependent cardiac declines support previous findings in mdx mice (Hacker et al. 2006) . Notably, these age-dependent declines in mdx cardiac function were not corrected by a year of quercetin ingestion ending at 14 months of age. These negative findings in quercetin-fed mdx mice are in contrast to a companion study, in which Mdx/Utrn +/− mice exhibited quercetin-dependent improvements in cardiac function up to the study end point at 10 months of age. Contrasts between the present investigation of aged mdx mouse strain versus younger Mdx/Utrn +/− mice are not necessarily surprising given that the latter mouse model is held to be a more severe dystrophic phenotype (Verhaart et al. 2012; van Putten et al. 2013) , and indeed, cardiac function in 10-month-old Mdx/Utrn +/− mice was more severely impaired than in 14-month-old mdx mice.
Collectively, these contrasting outcomes are very interesting and raise important new insights into the nuanced understanding of different murine muscular dystrophy models. Despite the previous (Ballmann et al. 2015) and present evidence that quercetin consumption benefits cardiac histological and biochemical outcomes, mouse age and strain considerations appear to be necessary before physiological changes attributable to treatment interventions can be observed. Thus, there is reason to believe that performance of cardiac scans of mdx mice at time points later than 14 months with more pronounced cardiac injury and dysfunction might have yielded quercetin treatment advantages not observed in the present study.
Indices of mitochondrial, PGC-1α and oxidative adaptations
Fundamental to the design of the present study was the fact that quercetin and other polyphenols stimulate the SIRT1-PGC-1α axis (Handschin et al. 2007; Davis et al. 2009; Gordon et al. 2013) and may serve to promote mitochondrial adaptations. Although previous studies in non-DMD models show increased gene expression of PGC-1α following quercetin enrichment (Davis et al. 2009 ), confirmation of protein expression outcomes is not well documented (Ballmann et al. 2015) . The present investigation demonstrates that long-term quercetin enrichment in mdx mice increased PGC-1α protein abundance in the dystrophic myocardium. Disparate findings between our previous and present study might be attributable to the age of the animals at the end of the experiment, in that suppressed mitochondrial biogenesis and PGC-1α abundance are characteristic of senescence (Short et al. 2005; Kalfalah et al. 2014) . Thus, the present findings of increased PGC-1α with quercetin enrichment might manifest more potently in aged mice and underscore the aforementioned considerations of animal age.
Several telling metrics for mitochondrial content were examined in the present study. Collective findings from 14-month-old hearts indicate that quercetin-fed mice exhibited a higher abundance of citrate synthase and electron transport complexes I-V. Although these secondary findings are not confirmatory, they provide compelling first evidence that quercetin consumption benefits mitochondrial capacity in the dystrophic heart. Bolstering evidence for mitochondrial adaptations is the fact that quercetin consumption was associated with elevations in the endogenous antioxidant enzyme SOD2, which is primarily found in mitochondria. This finding confirmed previous evidence that quercetin upregulates endogenous antioxidant enzymes (Vásquez-Garzón et al. 2009; Ballmann et al. 2015) . Independent of mitochondrial antioxidant content, quercetin feeding was also associated with elevated GPX protein content in mdx hearts and may represent fortification of the direct antioxidant capacity of quercetin (Boots et al. 2008a) . Our findings are in agreement with previous studies that show quercetin-induced increases in GPX expression (Coskun et al. 2005) and support a contributory role in the preservation of cardiac health (Matsushima et al. 2006) . Collectively, these findings support a role for quercetin-mediated protection of cardiac tissue, probably through mitochondrial fortification and improved redox status.
Damage and remodelling markers
Histological examination of remodelling indices suggests that long-term quercetin consumption in mdx mice exerted significant age-dependent improvements. Specifically, MMP9, fibronectin and H&E staining assays all indicated notable strain-dependent increases in the untreated mdx mice. From a statistical perspective, quercetin-fed mdx mice were numerically similar to C57 mice for MMP9 and H&E staining. Moreover, while the mean density of fibronectin staining was higher in quercetin-fed mdx mice, the value was roughly half that of the untreated mdx mice. These findings support our similar outcomes in hearts from younger mdx mice (Ballmann et al. 2015) and agree with the established time frame for pathological cardiac remodelling in the mdx model (Shirokova & Niggli, 2013 ). The present findings are supported by previous investigation of other polyphenol applications that prevent pathological cardiac remodelling (Hwang et al. 2008; Han et al. 2009 ). Although MMP9 levels were ß30% higher in mdx control mice versus quercetin-enriched animals, MMP9 protein abundance was not significantly altered between the quercetin-fed and control diet-fed mdx groups (P = 0.076). Alternatively, MMP activity might have been altered where protein abundance was not. In support, pharmacological inhibition of MMP9 activity in mdx mice is associated with improved muscular outcomes (Li et al. 2009 ). Although quercetin can inhibit MMP9 directly (Saragusti et al. 2010) , our present results are in agreement with our previous study, which indicated C. Ballmann and others that quercetin enrichment did not influence MMP9 accumulation in the mdx heart (Ballmann et al. 2015) . As increased MMP9 is a key factor in cardiac remodelling and cardiac dysfunction (Peterson et al. 2001; Moshal et al. 2008) , this finding might provide some insight into the negative cardiac performance outcomes in quercetin-fed mice. Nonetheless, the present data collectively indicate that quercetin enrichment prevents some indices of cardiac damage and appears to protect the dystrophic heart against pathological cardiac remodelling.
Indices of inflammatory signalling and mediation
Duchenne muscular dystrophy is commonly characterized by chronic inflammation, and anti-inflammatory countermeasures are essential in combating the disease. Among selected secondary post-mortem measurements performed in the present study, the findings of quercetin mediation of the inflammatory process are arguably the most modest. As NFκB signalling and protein are elevated in hearts from DMD patients (Acharyya et al. 2007) , we examined whether dietary quercetin enrichment affected the NFκB inflammatory pathway in the dystrophic myocardium. Most convincing in this regard are findings that quercetin feeding of mdx mice elicited notable alterations in the NFκB signalling pathway as evidenced by increased IKBα and levels of P-IKBα. Furthermore, quercetin enrichment lowered NFκB protein abundance versus mdx mice and indicates that the activated form, P-NFκB, was also lower in hearts from quercetin-fed mice. Therefore, downstream mediators of the NFκB pathway and the related inflammatory mediators, TGF-β1, CD64 and F4/80, were examined. Levels of COX2 were lower in hearts from quercetin-fed mice compared with either C57 or mdx mice. Bolstering this outcome are previous reports that polyphenols like quercetin suppress COX2 expression (Corona et al. 2007) . Transforming growth factor-β1, a key mediator in fibrotic deposition, was lower in quercetin-fed mdx mice, and this finding is in agreement with previous understanding that polyphenols possess the ability to blunt TGF-β1 expression (Phan et al. 2004) . To assess macrophage infiltration, CD64 and F4/80 were examined. Although quercetin enrichment did not alter CD64 (30% lower than control diet-fed mdx mice) in a statistically meaningful way, F4/80 was lower in dystrophic mouse hearts, and this suggests that less immune cell infiltration may have occurred. Overall, these data suggest that quercetin enrichment may have benefited immune cell infiltration and signalling, a finding that is thematically consistent with remodelling outcomes described earlier. It is, however, unclear whether this reduced inflammatory signalling and immune cell infiltration are direct results of the quercetin intervention or if they reflect overall improvement in the dystrophic myocardium.
Spontaneous physical activity
Among the most notable and perhaps most important findings of the present study were the collective outcomes that quercetin-fed mice performed more high-(wall pacing, running and jumping) and moderate-intensity activity (socializing and walking) than either age-matched mdx or C57 control mice. From a methodological perspective, activity counts were averaged from time periods in the respective light and dark cycles. Time-normalized scaling for the relative metabolic activity of low-, moderate-and higher-intensity activities to generate a cumulative activity metric confirmed that quercetin-fed mdx mice were the most active group of the study, whereas untreated mdx mice were the least active. The increased activity in quercetin-fed mdx mice, above and beyond that of C57 mice, potentially reflects adenosine receptor antagonism by quercetin, which is a well-described effect of many flavonoids (Alexander, 2006) . This point raises the intriguing possibility that the findings of increased physical activity in the present study may reflect concomitant benefits in the central nervous system, a possibility that requires additional investigation. Also of interest is the fact that an increased amount of forced exercise in mdx mice is associated with deleterious outcomes (Townsend et al. 2009 ). In contrast to this previous observation, the present findings of self-limited physical activity were associated with mitigated tissue remodelling and suggest that the mode of exercise might have important implications for future clinical applications. As such, self-limited discontinuous physical activity appears to have benefited the quercetin-treated mdx mice in the present study and highlights the need to assess further the impact of the exercise dose (intensity and duration, continuous versus discontinuous) on dystrophic outcomes. Based on this broader understanding, the present findings of spontaneous physical activity are viewed with optimism in combination with the other facets of this comprehensive investigation.
Conclusion
This longitudinal study provides important new information that chronic quercetin feeding at 0.2% of the total dietary intake provides robust cardioprotection against pathological tissue remodelling and inflammation in the mdx mouse. These findings are juxtaposed with improved markers of PGC-1α expression, mitochondrial content and endogenous antioxidant protein content. Although no quercetin-dependent benefits in cardiac function were observed, the dramatic increase in spontaneous physical activity without associated tissue pathology is probably telling. These findings build on our previous investigations using a similar methodological approach and highlight the pleiotropic benefits of quercetin ingestion.
From a methodological perspective, it is worth noting that despite the advantages of the 12 month longitudinal investigation and the end point at 14 months old used currently, extension of the treatment duration may be needed in order to observe quercetin-dependent alterations in cardiac function in mdx mice. In addition to age, the reader is cautioned against sweeping conclusions about the efficacy of quercetin in that examination of quercetin did yield physiological improvement in a more severe mouse model of DMD. On this point, a companion study also failed to observe sustained physiological benefit in quercetin-treated skeletal muscle (Selsby et al. 2016) . However, some of these differences might be attributable to differences in the mouse strain (Ballmann et al. 2017 ), a matter that will require additional investigation to resolve. Thus, translation of pragmatic and clinically feasible dietary interventions against DMD, such as application of dietary quercetin, require mindful consideration of the animal model inasmuch as other facets of the methodology. Based on tissue analyses, our results suggest that quercetin enrichment might be a potential therapy for dystrophic cardiac pathology that might improve clinical outcomes in DMD patients, although physiological outcomes do not support this conclusion in the present investigation.
editing and revision were performed by C.B., T.D., R.J.B., M.R., T.Q., J.T.S. and J.C.Q. All authors approved the final version of the manuscript and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All persons designated as authors qualify for authorship, and all those who qualify for authorship are listed. 
Funding
